RT Journal Article SR Electronic T1 Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.27.21257096 DO 10.1101/2021.05.27.21257096 A1 Anil Gupta A1 Yaneicy Gonzalez-Rojas A1 Erick Juarez A1 Manuel Crespo Casal A1 Jaynier Moya A1 Diego Rodrigues Falci A1 Elias Sarkis A1 Joel Solis A1 Hanzhe Zheng A1 Nicola Scott A1 Andrea L. Cathcart A1 Christy M. Hebner A1 Jennifer Sager A1 Erik Mogalian A1 Craig Tipple A1 Amanda Peppercorn A1 Elizabeth Alexander A1 Phillip S. Pang A1 Almena Free A1 Cynthia Brinson A1 Melissa Aldinger A1 Adrienne E. Shapiro A1 for the COMET-ICE Investigators YR 2021 UL http://medrxiv.org/content/early/2021/05/28/2021.05.27.21257096.abstract AB Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody designed to treat such high-risk patients early in the course of disease, thereby preventing Covid-19 progression.Methods In this ongoing, multicenter, double-blind, phase 3 trial, nonhospitalized patients with symptomatic Covid-19 and at least one risk factor for disease progression were randomized (1:1) to an intravenous infusion of sotrovimab 500 mg or placebo. The primary efficacy endpoint was the proportion of patients with Covid-19 progression, defined as hospitalization longer than 24 hours or death, through day 29.Results In this preplanned interim analysis, which included an intent-to-treat population of 583 patients (sotrovimab, 291; placebo, 292), the primary efficacy endpoint was met. The risk of Covid-19 progression was significantly reduced by 85% (97.24% confidence interval, 44% to 96%; P = 0.002) with a total of three (1%) patients progressing to the primary endpoint in the sotrovimab group versus 21 (7%) patients in the placebo group. All five patients admitted to intensive care, including one who died by day 29, received placebo. Safety was assessed in 868 patients (sotrovimab, 430; placebo, 438). Adverse events were reported by 17% and 19% of patients receiving sotrovimab and placebo, respectively; serious adverse events were less common with sotrovimab (2%) versus placebo (6%).Conclusion Sotrovimab reduced progression of Covid-19 in patients with mild/moderate disease, was well tolerated, and no safety signals were identified.Funded by Vir Biotechnology, Inc. and GlaxoSmithKline; ClinicalTrials.gov NCT04545060Competing Interest StatementAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Elias Sarkis, Joel Solis, Almena Free, and Adrienne E. Shapiro report acting as trial investigators for Vir Biotechnology and receiving non-financial support from Vir Biotechnology during the conduct of the study. Diego Rodrigues Falci reports acting as a trial investigator for Vir Biotechnology and receiving non-financial support from Vir Biotechnology during the conduct of the study; and personal fees and non-financial support from Pfizer and United Medical, non-financial support from Gilead Sciences and Merck Sharp & Dohme, and personal fees from GlaxoSmithKline outside the submitted work. Hanzhe Zheng, Christy M. Hebner, Jennifer Sager, Erik Mogalian, Elizabeth Alexander, and Melissa Aldinger are employees of Vir Biotechnology and report stock ownership in Vir Biotechnology and third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work. Nicola Scott and Amanda Peppercorn are employees of GlaxoSmithKline and report stock ownership in GlaxoSmithKline. Andrea L. Cathcart is an employee of Vir Biotechnology, reports stock ownership in Vir Biotechnology, third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work, and stock ownership in Gilead Sciences outside the submitted work. Craig Tipple is a former employee of GlaxoSmithKline and reports stock ownership in GlaxoSmithKline. Phillip S. Pang is an employee of Vir Biotechnology, reports stock ownership in Vir Biotechnology, third-party funding from GlaxoSmithKline to Vir Biotechnology for the submitted work, and a patent pending for sotrovimab for the treatment of COVID-19. Cynthia Brinson reports acting as a trial investigator for Vir Biotechnology and receiving non-financial support from Vir Biotechnology during the conduct of the study, and personal fees for advisory boards and speakers bureaus from Gilead Sciences and ViiV Healthcare outside the submitted work.Clinical TrialNCT04545060Funding StatementThis study was sponsored by Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following central and local institutional review boards (IRBs) and ethics committees (ECs): Advarra (central IRB), Columbia, Maryland, USA; Advarra (central IRB), Aurora, Ontario, Canada; Comité; de ética de la Investigación con medicamentos (CEIm), Consorci Corporació Sanitària Parc Tauli (central EC), Barcelona, Spain; Comité Nacional Transitorio de ética en Investigación para la Evaluación y Supervisión ética de los Ensayos Clínicos de la Enfermedad COVID-19 (central EC), Jesús María, Lima, Peru; Health Research Authority, London - London Bridge Research Ethics Committee (local EC), London, UK; and Ethik Kommission, Medizinische Universität Wien (local EC), Vienna, Austria. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is an interim analysis; the data will not be made available at this time.